Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor Corporation (NYSE: DXR) recently presented new findings at the Heart Failure Society of America’s Annual Scientific Meeting regarding its BVA-100® blood test, which measures anemia in heart failure patients. The study revealed that 62% of hospitalized heart failure patients suffer from true anemia, often undetected by standard tests. Daxor's BVA-100® can significantly improve patient outcomes, reducing 30-day mortality by 82% and readmissions by 56%. The company is also developing next-gen measurement technologies under contracts with the US Department of Defense.
Daxor Corporation (NYSE: DXR) presented new data on the cost-effectiveness of its BVA-100 blood volume analysis technology for treating heart failure at the Heart Failure Society of America’s Annual Scientific Meeting 2020. The study found an incremental cost-effectiveness ratio (ICER) of $10,200, which is significantly lower than other therapies. This leads to an average life extension of 2.32 quality-adjusted life years (QALYs). Daxor's technology is noted for improving patient outcomes while being economically advantageous for healthcare systems.
Daxor Corporation (NYSE: DXR) announces new data from the Mayo Clinic demonstrating that its Blood Volume diagnostic test, BVA-100, significantly outperforms the common weight loss metric in assessing heart failure treatment progress. Presented at the HFSA Annual Scientific Meeting 2020, the study highlights that traditional weight loss does not predict clinical outcomes, while Daxor's technology has been shown to reduce heart failure mortality by over 80% and readmissions by over 56%. Daxor aims to integrate its technology into standard practice to enhance patient care.
Daxor Corporation (NYSE: DXR) will exhibit at the Heart Failure Society of America’s Virtual Annual Scientific Meeting from September 30 to October 6, 2020. The company plans to showcase its BVA-100® blood test, highlighting new data on heart failure management through two posters: ‘Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients’ (Poster #132) and ‘Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients’ (Poster #331). The event aims to promote Daxor’s technology and enhance heart failure outcomes.
Daxor Corporation (NYSE: DXR) will showcase innovative data at the Heart Failure Society of America's Virtual Annual Scientific Meeting from September 30 to October 6, 2020. The company will present its BVA-100® blood test, aimed at improving heart failure outcomes. Key presentations include 'Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients' and 'Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients.' CEO Michael Feldschuh emphasizes Daxor's commitment to enhancing heart failure treatment through advanced blood volume measurement technology.
Daxor Corporation (NYSE: DXR) announced its participation in the inaugural Sepsis Alliance Summit on September 17, 2020. CEO Michael Feldschuh will discuss the BVA-100 blood test's role in improving sepsis care through insights into volume derangements and capillary permeability in critically-ill patients. The BVA-100 test, linked to significant clinical benefits, has shown 66% lower mortality rates in patients receiving BVA-guided care. September is also National Sepsis Awareness Month, highlighting the urgent need to combat sepsis, which affects 1.7 million adults in the U.S. annually.
Daxor Corporation (NYSE: DXR) will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 PM ET. During this event, President & CEO Michael Feldschuh will present updates regarding the company's BVA-100 technology, a diagnostic tool for blood volume measurement. The conference runs from September 14-16, 2020, featuring opportunities for one-on-one meetings with investors. Daxor's technology aims to enhance treatment strategies and patient outcomes in critical medical conditions.
Daxor Corporation (NYSE: DXR) will present at the LD 500 Virtual Investor Conference from September 1-4, 2020. CEO Michael Feldschuh is scheduled to present on September 2 at 9:20 am ET, followed by a Q&A session. The presentation will cover updates on the company's diagnostic division and ongoing clinical trials. Investors can request one-on-one meetings with Feldschuh during the event. The presentation will be available for live streaming and replay here.
Daxor Corporation (NYSE: DXR) has announced a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation to research its BVA-100 diagnostic test for measuring circulatory blood volume in traumatic injuries. CEO Michael Feldschuh emphasized the BVA-100's potential to enhance battlefield resuscitation practices by providing precise blood volume measurements, improving survival rates. This partnership focuses on critical conditions like hemorrhage and trauma, and aims to translate military advancements to civilian care.
Daxor Corporation (DXR) announced a registered direct offering involving 125,000 shares of common stock from the Company and 225,000 shares from the Estate of Joseph Feldschuh at $20.00 per share, generating gross proceeds of $7.0 million. The Company plans to allocate $2.5 million for working capital and corporate purposes. The offering is set to close around July 22, 2020. H.C. Wainwright & Co. is the exclusive placement agent.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
